Literature DB >> 1653908

Spindle-cell glioblastoma or gliosarcoma?

H Jones1, P V Steart, R O Weller.   

Abstract

'Gliosarcomas' have long been considered to be mixed gliomas and sarcomas. The present study failed to define criteria which clearly delineate 'gliosarcomas' from glioblastoma multiforme and suggests that 'gliosarcomas' should be considered as spindle cell glioblastomas. A total of six cases originally diagnosed as 'gliosarcomas' were compared with four cases of glioblastoma multiforme. No clinical or prognostic features were defined which would clearly separate 'gliosarcomas' from glioblastoma multiforme. Macroscopically, biopsies from 'gliosarcomas' ranged from firm, apparently well-circumscribed tumours to poorly circumscribed lesions with a soft consistency resembling glioblastoma multiforme. Histology revealed a continuous spectrum in which 'gliosarcomas' with large reticulin-rich areas of spindle cells merged with typical glioblastomas containing only small islands of spindle cells and reticulin staining. Immunocytochemistry for glial fibrillary acidic protein (GFAP); S100 protein and alpha-smooth muscle actin (ASMA) showed that the majority of cells in reticulin-poor areas of 'gliosarcoma' and glioblastomas expressed S100 protein and GFAP; many expressed ASMA and some expressed both GFAP and ASMA. Spindle cells in reticulin-rich areas of 'gliosarcomas' and glioblastomas most frequently expressed ASMA but many cells also expressed S100 protein and GFAP; some cells expressed both GFAP and ASMA. The results of this study and a review of the literature suggests that there is a clinical, radiological and pathological continuum with glioblastoma and 'gliosarcoma' at different ends of the spectrum. It is suggested, therefore, that most, if not all, 'gliosarcomas' be redesignated as spindle cell glioblastomas and not be considered as a mixture of glioma and sarcoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1653908     DOI: 10.1111/j.1365-2990.1991.tb00713.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  10 in total

1.  Adipose tissue and smooth muscle in a primitive neuroectodermal tumor of cerebrum.

Authors:  L Selassie; R Rigotti; J J Kepes; J Towfighi
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

2.  Genetic profile of gliosarcomas.

Authors:  R M Reis; D Könü-Lebleblicioglu; J M Lopes; P Kleihues; H Ohgaki
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

3.  Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma.

Authors:  Cynthia Jimenez; Martin Powers; Andrew T Parsa; Christine Glastonbury; Jill M Hagenkord; Tarik Tihan
Journal:  J Neurooncol       Date:  2011-05-01       Impact factor: 4.130

4.  Cellular components of microvascular proliferation in human glial and metastatic brain neoplasms. A light microscopic and immunohistochemical study of formalin-fixed, routinely processed material.

Authors:  P Wesseling; J J Vandersteenhoven; B T Downey; D J Ruiter; P C Burger
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

5.  Gliosarcomas: analysis of 11 cases do two subtypes exist?

Authors:  Maurizio Salvati; Emanuela Caroli; Antonino Raco; Felice Giangaspero; Roberto Delfini; Luigi Ferrante
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 6.  Gliofibromas (including malignant forms), and gliosarcomas: a comparative study and review of the literature.

Authors:  M Cerda-Nicolas; J J Kepes
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

7.  Childhood's gliosarcomas: pathological and therapeutical considerations on three cases and critical review of the literature.

Authors:  Maurizio Salvati; Jacopo Lenzi; Christian Brogna; Alessandro Frati; Manolo Piccirilli; Felice Giangaspero; Antonino Raco
Journal:  Childs Nerv Syst       Date:  2006-03-16       Impact factor: 1.475

8.  Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.

Authors:  J P Robinson; M W VanBrocklin; A R Guilbeault; D L Signorelli; S Brandner; S L Holmen
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

9.  Interphase cytogenetics of glioblastoma and gliosarcoma.

Authors:  W Paulus; A Bayas; G Ott; W Roggendorf
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography.

Authors:  Yann Jamin; Jessica K R Boult; Jin Li; Sergey Popov; Philippe Garteiser; Jose L Ulloa; Craig Cummings; Gary Box; Suzanne A Eccles; Chris Jones; John C Waterton; Jeffrey C Bamber; Ralph Sinkus; Simon P Robinson
Journal:  Cancer Res       Date:  2015-02-11       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.